Skip to main content
logo
Kukje Pharma Co., Ltd. (KRX:002720)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,310.00
+35.00 (1.07%)
Last updated: Aug 6, 2026, 2:35 PM KST

Kukje Pharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
5,9925,6985,205-8,4153,557-1,559
Depreciation & Amortization
3,2793,2263,2034,2044,4884,419
Asset Writedown & Restructuring Costs
202030.131,874502.66-
Loss (Gain) From Sale of Investments
165.12185.97180.1-22.1116.73-13.21
Loss (Gain) on Equity Investments
-----23.2172.91
Provision & Write-off of Bad Debts
-385.61-464.69349.37-1,249-1,313-1,288
Other Operating Activities
2,4172,5173,1111,7553,5502,369
Change in Accounts Receivable
-6,863-4,503-2,334565.754,6484,595
Change in Inventory
-2,689-2,882-949.391,290-4,7893,261
Change in Accounts Payable
3,4206,070-4,39611,579711.15933.17
Change in Other Net Operating Assets
-2,430-4,032-458.16-8,006-4,845-3,192
Operating Cash Flow
2,9275,8353,9403,5756,5049,597
Operating Cash Flow Growth
-11.45%48.11%10.20%-45.03%-32.23%88.18%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,859-3,619-2,911-1,046-1,259-1,892
Sale of Property, Plant & Equipment
12.1712.48110.35305.7481.4423.36
Sale (Purchase) of Intangibles
-287.46-249.66-5.73--18-68.5
Investment in Securities
-433.24-433.24-1,746190--1,361
Other Investing Activities
313.9133.36-207.63-624.89-151.54-83.05
Investing Cash Flow
-4,253-4,156-4,760-1,175-1,347-3,382

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-8,00010,5007,900--
Total Debt Issued
17,0008,00010,5007,900--
Short-Term Debt Repaid
--7,000-11,500-4,900-7,000-2,000
Long-Term Debt Repaid
--183.99-197.65-358.95-433.03-388.36
Total Debt Repaid
-16,188-7,184-11,698-5,259-7,433-2,388
Net Debt Issued (Repaid)
811.97816.01-1,1982,641-7,433-2,388
Issuance of Common Stock
138.74138.74----
Repurchase of Common Stock
----31.07-40.62-45.54
Dividends Paid
-610.88-610.88----
Other Financing Activities
-0-00000
Financing Cash Flow
339.84343.87-1,1982,610-7,474-2,434

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
149.311.66105.8740.82-10.3871.65
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
-837.552,025-1,9115,051-2,3273,853

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-932.072,2161,0292,5295,2457,705
Free Cash Flow Growth
-115.42%-59.32%-51.78%-31.93%-
Free Cash Flow Margin
-0.52%1.26%0.66%1.87%4.14%6.43%
Free Cash Flow Per Share
-45.29108.7350.60124.88258.88380.18
Levered Free Cash Flow
1,402-247.66-3,1358,5503,5045,485
Unlevered Free Cash Flow
1,934320.1-2,3819,4504,1295,920

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
887.88930.691,2201,4181,003722.5
Cash Income Tax Paid
1,8241,9621,5622,269-559.712,491
Change in Working Capital
-8,561-5,347-8,1385,429-4,2745,597